Relay Therapeutics, Inc. — fact timeline

Relay Therapeutics, Inc.: Increased authorized shares of common stock from 300,000,000 to 450,000,000 (effective 2026-06-09).

“On June 9, 2026, Relay Therapeutics, Inc. (the “Company”) filed a Certificate of Second Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 300,000,000 shares to 450,000,000 shares.”

Relay Therapeutics, Inc. shareholders approved Approval of amendment to the Fourth Amended and Restated Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 450,000,000 at the 2026-06-09 meeting.

“The Company’s stockholders approved an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 shares to 450,000,000 shares, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 170,323,683 909,020 23,821 0”

Relay Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 171,030,133 204,449 21,942 0”

Relay Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-06-09 meeting.

“The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 143,849,919 3,154,118 51,787 24,200,700”

Relay Therapeutics, Inc. shareholders approved Election of class III directors for a three-year term ending at the 2029 annual meeting at the 2026-06-09 meeting.

“The Company’s stockholders elected each of the following individuals to serve as class III directors for a three-year term ending at the Company’s 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Name Votes For Votes Withheld Broker Non-Votes Douglas S. Ingram 120,859,999 26,195,825 24,200,700 Claire Mazumdar, Ph.D. 122,859,060 24,196,764 24,200,700”

Relay Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters valued at approximately $296.8 million (effective 2026-05-20).

“On May 20, 2026, Relay Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 22,916,667 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $12.00 per share.”

Relay Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue 3.0, net income -73.3, EPS -0.41.

“--- EX-99.1 Exhibit 99.1 Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced”

Relay Therapeutics, Inc.: Amended and restated bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims (effective 2026-03-06).

“On March 6, 2026, the Board of Directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s amended and restated bylaws (the “A&R Bylaws”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.”

Claire Mazumdar was appointed as Class III Director at Relay Therapeutics, Inc..

“On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph.D., MBA as a member of the Board, effective as of June 9, 2025.”

Relay Therapeutics, Inc. reported first quarter 2024 results: revenue $10.0 million, net income $81.4 million, EPS $0.62.

“The company expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026. Revenue: Revenue was $10.0 million for the first quarter of 2024, as compared to $0.2 million for the first quarter of 2023. The increase was primarily due to a payment of $10.0 million in connection with a”

Relay Therapeutics, Inc. reported the full year 2023 results: revenue Revenue was $25.5 million for the full year 2023, net income Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79, EPS $2.79.

“Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79”

Relay Therapeutics, Inc. reported the fourth quarter of 2023 results: net income Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67, EPS $0.67.

“Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67”

Relay Therapeutics, Inc. entered into securities purchase agreement with Nextech Crossover I SCP valued at 2,500,000 shares at $12.00 per share for aggregate gross proceeds of approximately $30 million (effective 2024-01-08).

“On January 8, 2024, Relay Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Nextech Crossover I SCP (the “Purchaser”), for the private placement (the “Private Placement”) of 2,500,000 shares (the “PIPE Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at $12.00 per share.”

Relay Therapeutics, Inc. reported the quarter ended September 30, 2023 results: revenue $25.2 million, net income $65.7 million, EPS $0.54.

“Therapeutics expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026. Revenue: Revenue was $25.2 million for the third quarter of 2023, as compared to $0.3 million for the third quarter of 2022. The increase was primarily due to the recognition of previously received milestone”

Relay Therapeutics, Inc. reported second quarter 2023 results: net income Net loss was $98.5 million, EPS net loss per share of $0.81.

“Net loss was $98.5 million for the second quarter of 2023, or a net loss per share of $0.81”

Relay Therapeutics, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2023-05-31 meeting.

“Proposal 3. Ratification of appointment of independent registered public accounting firm. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 112,171,015.00 11,640.00 40,019.00 0.00”

Relay Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2023-05-31 meeting.

“Proposal 2. Non-binding advisory vote on executive compensation. The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 97,777,468.59 6,901,684.00 70,089.00 7,473,432.40”

Relay Therapeutics, Inc. shareholders approved Election of directors at the 2023-05-31 meeting.

“Proposal 1. Election of directors. The Company’s stockholders elected each of the following individuals to serve as class III directors for a three-year term ending at the Company’s 2026 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Name Votes For Votes Withheld Broker Non-Votes Douglas S. Ingram 103,319,668.59 1,429,573.00 7,473,432.40 Sekar Kathiresan, M.D. 104,644,413.59 104,828.00 7,473,432.40 Jami Rubin 94,814,052.83 9,935,188.75 7,473,432.40”

Relay Therapeutics, Inc. reported the first quarter of 2023 results: net income $94.2 million, EPS $0.78.

“Net loss was $94.2 million for the first quarter of 2023, or a net loss per share of $0.78, as compared to a net loss of $62.0 million for the first quarter of 2022, or a net loss per share of $0.57.”

Relay Therapeutics, Inc. reported financial results for the full year 2022.

“On February 23, 2023, Relay Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2022.”

Relay Therapeutics, Inc. reported the fourth quarter of 2022 results: net income $67.5 million, EPS $0.56.

“Net loss was $67.5 million for the fourth quarter of 2022, or a net loss per share of $0.56”

Relay Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76, EPS $0.76.

“Relay Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.”

Sekar Kathiresan was appointed as Director at Relay Therapeutics, Inc..

“On July 25, 2022, the board of directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Sekar Kathiresan, M.D. to the Board as a class III director to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.”

Dipchand (Deep) Nishar resigned as Class III director at Relay Therapeutics, Inc..

“On and effective as of December 8, 2021, Dipchand (Deep) Nishar tendered his resignation as a Class III director of the board of directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”).”